Loading
Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines.
Igor Puzanov is Director of the Early Phase Clinical Trials Program and Chief of the Melanoma Section at Roswell Park Comprehensive Cancer Center. He is a melanoma oncologist known for leading the first study of the oncolytic virus talimogene laherparepvec combined with ipilimumab, and for co-writing the guidelines on managing immune-related toxicity. His selected paper reports talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB to IV melanoma. He now directs Roswell Park's phase 1 programme and continues to work on oncolytic viruses.
| Title | Journal | Year |
|---|---|---|
| Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma | Journal of Clinical Oncology | 2016 |
Shares Talimogene laherparepvec, Melanoma.
Shares Oncolytic viruses, Melanoma.
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.